Table 3.
Effect of BIBP3226 in slices (one to four per animal) from chronically OA- (n = 7) or VPA- (n = 8) treated P13–P15 animals
| OA | VPA | |||||
|---|---|---|---|---|---|---|
| ACSF | BIBP3226 | Washout | ACSF | BIBP3226 | Washout | |
| Oscillation amplitude | 5246 ± 1001 | 6262 ± 1399 | 5053 ± 986 | 3209 ± 943 p < 0.5 | 4222 ± 1253 | 3806 ± 1117 |
| Normalized | 1 | 1.17 ± 0.07 | 0.98 ± 0.06 | 1 | 1.28 ± 0.05 p < 0.5 | 1.16 ± 0.09 |
| τ Oscillation | 2889 ± 576 | 3046 ± 587 | 2839 ± 584 | 1839 ± 315 p < 0.5 | 2157 ± 398 | 1986 ± 405 |
| Normalized | 1 | 1.05 ± 0.02 | 0.98 ± 0.03 | 1 | 1.17 ± 0.05 p < 0.05* | 1.05 ± 0.05 |
| Oscillation period (ms) | 315 ± 13 | 319 ± 13 | 326 ± 14 | 272 ± 11 p < 0.05* | 276 ± 10 | 280 ± 10 |
| Nonoscillatory amplitude | 1614 ± 536 | 1673 ± 611 | 1332 ± 532 | 1474 ± 474 p > 0.5 | 1736 ± 511 | 1363 ± 397 |
| Normalized | 1 | 1.00 ± 0.12 | 0.79 ± 0.14 | 1 | 1.22 ± 0.12 p < 0.05* | 1.05 ± 0.15 |
| τ Nonoscillatory | 6846 ± 2624 | 4217 ± 1376 | 3674 ± 1442 | 2130 ± 403 p < 0.5 | 1984 ± 494 | 1714 ± 185 |
| Normalized | 1 | 0.86 ± 0.08 | 0.80 ± 0.11 | 1 | 0.93 ± 0.08 p > 0.5 | 0.82 ± 0.09 |
Parameters for evoked oscillations in nRt according to the equation given in Materials and Methods. To identify changes caused by VPA treatment alone, comparisons were made between raw data in control conditions (ACSF) for slices from OA- and VPA-treated animals. To assess differential effects of VPA treatment on NPY signaling, comparisons were made between normalized data during BIBP3226 superfusion (Y1 receptor blockade) in slices from OA- and VPA-treated animals. The asterisks denote statistical significance in comparisons between OA and VPA, either in baseline parameters (see column VPA/ACSF for raw data) or in degree of change upon BIBP3226 appplication (see column VPA/BIBP3226 for normalized data).